Urgent.News

What's breaking now, across thousands of outlets.

World

Seoul turns iconic landmarks into free 3D backdrops for webtoon creators

Seoul is turning some of its most recognizable landmarks into ready-made digital backdrops, giving webtoon and animation creators around the world free access to 3D versions of the city's streets, shopping districts and Han River waterfront. The Seoul Metropolitan Government said Friday it will distribute 13 digital assets featuring locations across the capital, including Dongdaemun Design Plaza…

Seoul turns iconic landmarks into free 3D backdrops for webtoon creators

Seoul is making 13 digital assets featuring iconic landmarks available for free use by webtoon and animation creators worldwide. The Seoul Metropolitan Government announced the initiative on Friday, providing access to 3D versions of various locations across the city. These digital backdrops include Dongdaemun Design Plaza (DDP), Yeouido Park, Banpo Hangang Park, and other popular spots.

The collection encompasses both outdoor and indoor settings, with 5 outdoor locations and 8 indoor environments. The outdoor areas focus on two districts around Dongdaemun, Heunginji Gate, Cheonggye Stream, and three locations along the Han River. Nighttime scenes featuring illuminated buildings, fireworks, and views of Banpo Bridge are also included to cater to a variety of genres.

Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Other reports of this story

Every outlet that reported this, and when →

Read the original at koreatimes.co.kr →

More in World

German Court Overturns Keytruda SC Sales Ban, Opening Door to European Expansion

The path to market entry in Germany, Europe’s largest pharmaceutical market, has opened for Keytruda SC, the subcutaneous formulation of the immuno-oncology drug developed by U.S.-based Merck (MSD)…

  • German court overturns ban on Keytruda SC sales, allowing European expansion.
  • Merck wins patent disputes in Germany and U.S., clearing path for drug's entry.
  • Keytruda SC's subcutaneous formulation reduces treatment time to one to two minutes.

More from Friday 20 November →